Brean Murray Carret & Co. Starts IntelliPharmaCeutics International (IPCI) at Buy

Article Stock Quotes (1) Comments (0)

Brean Murray Carret & Co. initiates coverage on IntelliPharmaCeutics International (NASDAQ: IPCI) with a Buy. PT $7.00.

Brean analyst said, "We see several near-term catalysts for Intellipharmaceutics, notably its second Phase 1 Rexista dataset, a potential Rexista partnership, and initiation of Phase 3 Rexista trials. Positive Phase 1 data for Rexista could lead to a partnership that generates a significant upfront payment. Also, Phase 3 initiation, expected in 1Q13, would clarify Rexista’s potential market timing."

For an analyst ratings summary and ratings history on IntelliPharmaCeutics International click here. For more ratings news on IntelliPharmaCeutics International click here.

Shares of IntelliPharmaCeutics International closed at $2.86 yesterday, with a 52 week range of $2.40-$3.82.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Deutsche Bank Starts Kodiak Oil & Gas (KOG) at Hold
• Topeka Capital Starts Spansion (CODE) at Buy
• Dollar Tree (DLTR) Beats But Looks Stretched - Jefferies

Create E-mail Alert Related Categories

New Coverage

Related Entities

Brean Murray Carret & Co.

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?